본문으로 건너뛰기
← 뒤로

EBV-Positive Diffuse Large B-Cell Lymphoma (DLBCL): An Assessment and a Roadmap.

1/5 보강
Journal of medical virology 📖 저널 OA 55.6% 2022: 0/1 OA 2023: 0/1 OA 2024: 0/2 OA 2025: 6/10 OA 2026: 9/13 OA 2022~2026 2025 Vol.97(12) p. e70722
Retraction 확인
출처

Porcu P, Masel R, Kendsersky N, Noel C, Weigel C, Khoo AS

📝 환자 설명용 한 줄

Diffuse large B-cell Lymphoma (DLBCL) is the most common lymphoma subtype worldwide.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Porcu P, Masel R, et al. (2025). EBV-Positive Diffuse Large B-Cell Lymphoma (DLBCL): An Assessment and a Roadmap.. Journal of medical virology, 97(12), e70722. https://doi.org/10.1002/jmv.70722
MLA Porcu P, et al.. "EBV-Positive Diffuse Large B-Cell Lymphoma (DLBCL): An Assessment and a Roadmap.." Journal of medical virology, vol. 97, no. 12, 2025, pp. e70722.
PMID 41307390 ↗
DOI 10.1002/jmv.70722

Abstract

Diffuse large B-cell Lymphoma (DLBCL) is the most common lymphoma subtype worldwide. The Epstein Barr Virus (EBV) is a human DNA virus associated with a spectrum of human malignancies. EBV is detected in 5% to 15% of DLBCL tumors with no history of immunosuppression. Early reports of EBV-positive DLBCL suggested distinct clinical presentation, unique tumor microenvironment (TME), and inferior survival compared to EBV-negative DLBCL. A better definition of EBV-positive cases treated with modern chemo-immunotherapy has recently improved our understanding of this entity. Recent studies have provided initial insights into the distinct mutational landscape and immune microenvironment of EBV-positive DLBCL and identified EBV as an independent prognostic biomarker in DLBCL. Despite these advances, fundamental questions remain. We provide an overview of emerging clinical and molecular aspects of EBV-positive DLBCL and discuss recent efforts to develop EBV-targeting therapies. We also discuss key research questions in EBV-positive DLBCL.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반